News Conference News EHRA 2023 EPs Push for More Involvement in TAVI Heart Team Discussions Michael O'Riordan April 21, 2023
News Conference News EHRA 2023 ‘Marshall Plan’ Ablation Superior to Pulmonary Vein Isolation in Persistent AF Michael O'Riordan April 20, 2023
News Conference News EHRA 2023 Novel Score Identifies HF Patients With AF Who Respond to Ablation Michael O'Riordan April 19, 2023
News Conference News EHRA 2023 Synchronized LV Pacing Not Superior to Conventional CRT in Heart Failure Michael O'Riordan April 18, 2023
News Conference News EHRA 2023 Outcomes Just as Good With Delayed vs Early AF Ablation Michael O'Riordan April 17, 2023
News Conference News EHRA 2023 Esophageal Fistula Still a Rare but Deadly Complication of AF Ablation: POTTER-AF Michael O'Riordan April 17, 2023
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis Michael O'Riordan March 10, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2023 Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions Michael O'Riordan March 07, 2023
News Conference News ACC 2023 No Downside to Immediate Complete Revascularization in ACS: BIOVASC Michael O'Riordan March 06, 2023
News Conference News ACC 2023 For Complex PCI, Intravascular Imaging Lowers Risk of TVF Michael O'Riordan March 05, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News AHA 2022 Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World Michael O'Riordan November 10, 2022
News Conference News AHA 2022 Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION Michael O'Riordan November 09, 2022
News Conference News AHA 2022 Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study Michael O'Riordan November 07, 2022
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022